Cannabis, PTSD, and Veterans: New PubMed Findings Explained

What the Latest Peer‑Reviewed Studies Show About Cannabis and PTSD in Veterans

All studies cited below come from PubMed, the U.S. National Library of Medicine’s database of peer‑reviewed research. They provide a snapshot of current scientific exploration into the relationship between cannabis use and post‑traumatic stress disorder (PTSD) among veterans. This overview is meant for general education only and is not medical advice. If you are considering cannabis for PTSD, please discuss it with a licensed health professional.

1. Microglia, THC, and Fear Memory – A Sex‑Specific Look

A 2025 investigation published in Neuropsychopharmacology examined how the main psychoactive component of cannabis, delta‑9‑tetrahydrocannabinol (THC), influences fear memory reconsolidation in a PTSD context. Researchers focused on microglia—immune cells in the brain that become particularly active in fear circuitry. They found that THC’s ability to disrupt fear memory reconsolidation is linked to signaling through cannabinoid type‑1 receptors (CB1) and peroxisome proliferator‑activated receptor gamma (PPARγ). Both receptors are involved in neuroimmune modulation, including microglial activity. The study highlighted that these mechanisms may differ between sexes, suggesting that male and female brains could respond differently to THC in the context of fear processing.

• Key insight: THC may alter fear memory via CB1 and PPARγ pathways.
• Implication: Sex differences could influence how cannabis affects PTSD symptoms.

Read the full study on PubMed: https://pubmed.ncbi.nlm.nih.gov/42106477/

2. Psychiatric Comorbidities in Substance Use Disorders – Sex-Based Differences

In a 2023 cross‑sectional analysis from The American Journal of Psychiatry, researchers used data from state‑funded mental health programs to assess the odds of psychiatric comorbidities among individuals diagnosed with opioid, alcohol, or cannabis dependence. The study specifically examined whether these odds varied by sex. Findings indicated that while substance use disorders are linked to higher rates of psychiatric comorbidities, the magnitude of this association was not consistent across sexes for all substances. For cannabis dependence, the relationship with additional psychiatric conditions appeared less pronounced than for opioid or alcohol dependence.

• Key insight: Cannabis users may have a different pattern of psychiatric comorbidity compared to other substances.
• Implication: Sex may influence the risk profile for comorbid mental health conditions.

Read the full study on PubMed: https://pubmed.ncbi.nlm.nih.gov/41807315/

3. Safety and Mental Health Outcomes of Oregon’s Regulated Psilocybin Services

A 2024 cohort study published in JAMA Network Open evaluated the safety and mental health outcomes of Oregon’s newly regulated psilocybin services. Participants from 24 licensed centers were followed through June 2026. While the study focuses on psilocybin rather than cannabis, it provides context for how state‑regulated psychedelic therapies are monitored. The findings reported no serious adverse events and noted improvements in several mental health measures among participants, underscoring the importance of structured, supervised environments for psychedelic use.

• Key insight: Structured psychedelic programs can be safe with proper oversight.
• Implication: Similar considerations may apply to medical cannabis use, especially regarding dosing and setting.

Read the full study on PubMed: https://pubmed.ncbi.nlm.nih.gov/42616497/

4. Cannabis Use During Pregnancy and Postpartum Mental Health

A 2023 article in the American Journal of Perinatology explored the association between cannabis use, intimate partner violence (IPV) during pregnancy, and postpartum mental health. The study found that women who used cannabis while pregnant and experienced IPV had poorer postpartum mental health outcomes compared to those who did not use cannabis or did not experience IPV. Although the research is not specific to veterans, it highlights how cannabis use can interact with other risk factors to influence mental health.

• Key insight: Cannabis use during pregnancy may compound mental health risks in the context of IPV.
• Implication: Veterans who are pregnant should consider these findings when discussing cannabis use.

Read the full study on PubMed: https://pubmed.ncbi.nlm.nih.gov/41412165/

5. Adolescent E‑Cigarette Use – A Sex‑Stratified Machine Learning Analysis

In a 2024 study from Drug and Alcohol Dependence Reports, researchers used machine learning to identify predictors of e‑cigarette use among 9th graders in Southern California, with a focus on sex differences. While this research does not involve cannabis directly, it illustrates how emerging technologies can uncover nuanced patterns of substance use that differ between males and females. Such approaches could eventually be applied to cannabis use studies to better understand sex‑specific risk factors.

• Key insight: Predictive modeling can reveal sex‑specific drivers of substance use.
• Implication: Similar methods may help identify distinct risk profiles for cannabis use in veterans.

Read the full study on PubMed: https://pubmed.ncbi.nlm.nih.gov/41859247/

6. Scoping Review of Medical Cannabis for PTSD

A 2025 scoping review published in the Journal of Cannabis Research synthesized evidence from randomized controlled trials and observational studies on medical cannabis for PTSD. The review noted that while some studies suggest potential benefits, the overall evidence remains fragmented. Current treatment guidelines still recommend against using cannabinoids for PTSD, largely due to limited and inconsistent data. The authors called for more rigorous research to clarify efficacy, safety, and optimal dosing strategies.

• Key insight: Evidence for cannabis in PTSD is still emerging and inconclusive.
• Implication: Veterans should approach cannabis use with caution and under professional guidance.

Read the full study on PubMed: https://pubmed.ncbi.nlm.nih.gov/42210342/

What Does This Mean for Veterans?

Across these studies, several themes emerge: the biological mechanisms of THC may differ by sex; cannabis use patterns intersect with other psychiatric conditions; and the broader field of psychedelic therapy emphasizes the need for regulated, supervised use. Importantly, the current scientific literature does not provide definitive answers about cannabis as a treatment for PTSD. The evidence base is still developing, and most studies highlight the necessity of careful monitoring and professional oversight.

Key takeaways for veterans considering medical cannabis:

• Sex differences may influence how THC affects fear memory and psychiatric comorbidities.
• Cannabis use does not eliminate the risk of additional psychiatric conditions, especially when combined with other factors.
• Regulated therapeutic settings, whether for psilocybin or cannabis, appear to reduce safety concerns.
• Current guidelines do not endorse cannabis for PTSD, and evidence remains inconclusive.

Next Steps

Because the science is evolving, it is essential to discuss any interest in medical cannabis with a licensed healthcare provider who can consider your personal medical history, current medications, and treatment goals. Veterans may also benefit from specialized support services that address both PTSD and substance use.

For more detailed information on each study, visit the PubMed links provided above. Remember, these studies offer insights but do not substitute for personalized medical guidance.